Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

Last updated: June 24, 2013
Sponsor: Allergan
Overall Status: Completed

Phase

1

Condition

Alopecia

Hair Loss

Treatment

N/A

Clinical Study ID

NCT01189279
192024-053
  • Ages 18-64
  • All Genders

Study Summary

This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia. Two formulations of bimatoprost will be investigated in Part 1 and a third formulation of bimatoprost will be investigated in Part 2. Part 2 will begin after Part 1 has completed.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Males with moderate male-pattern baldness (androgenic alopecia)

  • Females with moderate female pattern hair loss

  • Non-smoker or smoker with at least 30 days abstinence from smoking/usingnicotine-containing products

Exclusion

Exclusion Criteria:

  • Any dermatological condition of the scalp other than androgenic alopecia (males) orfemale pattern hair loss (females)

  • Use of bimatoprost or other prostaglandin analogs within 3 months

  • Prior use of scalp hair growth treatment (eg, finasteride, minoxidil) within 6 months

  • Any prior hair growth procedures (eg, hair transplant or laser)

  • Blood donation or equivalent blood loss within 90 days

  • History of alcohol or drug addiction

Study Design

Total Participants: 42
Study Start date:
October 01, 2010
Estimated Completion Date:
February 28, 2011

Connect with a study center

  • Tempe, Arizona
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.